肝动脉化疗栓塞术联合深部热疗治疗晚期原发性肝癌的效果分析

Effect analysis of hepatic arterial chemoembolization combined with deep hyperthermia in the treatment of advanced primary liver cancer

目的探讨晚期原发性肝癌患者应用肝动脉化疗栓塞术联合深部热疗治疗的临床效果。方法将2015年10月~2017年10月来我院接受治疗的82例晚期原发性肝癌患者选为观察对象,依照随机数字表法分为对照组(n=41)和试验组(n=41)。对照组患者给予肝动脉化疗栓塞术治疗,试验组患者在对照组基础上给予深部热疗治疗,对两组患者临床疗效、甲胎蛋白(AFP)水平、Karnofsky(KPS)评分及不良反应发生率进行统计比较。结果试验组患者临床总有效率明显高于对照组,分别为70.7%、41.5%,差异有统计学意义(P<0.05)。两组患者治疗后AFP水平明显降低,与治疗前相比,差异有统计学意义(P<0.05),且试验组患者明显低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后KPS评分明显升高,与治疗前相比,差异有统计学意义(P<0.05),且试验组患者明显高于对照组,差异有统计学意义(P<0.05)。两组患者胃肠道反应、肝功能损害、发热、白细胞下降发生率比较,差异无统计学意义(P>0.05)。结论晚期原发性肝癌患者应用肝动脉化疗栓塞术联合深部热疗治疗的临床效果更加确切,不仅可以缩小肿瘤,还可以提高生活质量,是一种值得临床推广与应用的治疗方案。

Objective To investigate the clinical effect of hepatic arterial chemoembolization combined with deep hy- perthermia in patients with advanced primary liver cancer. Methods 82 patients with advanced primary liver cancer who were treated in our hospital from October 2015 to October 2017 were selected as observation subjects and divided into control group （n=41） and experimental group （n=41） according to the random number table method. The patients in the control group were treated with hepatic arterial chemoembolization. The patients in the experimental group were treated with deep hyperthermia on the basis of the treatment of the control group. The clinical efficacy, AFP level, karnofsky （KPS） score, and incidence of adverse reactions were compared between the two groups of patients. Results The total clinical efficiency of the experimental group 70.7% was significantly higher than that of the control group （41.5%）, and the difference was statistically significant （P〈0.05）. The AFP levels in both groups after treatment were significantly lower than those before treatment, and the difference was significant （P〈0.05）. And the AFP levels in the experimental group were significantly lower than those in the control group, with statistically significant difference （P〈0.05）. The KPS scores of the two groups after treatment were significantly higher than those before treatment （P〈0.05）. The KPS scores in the experimental group were significantly higher than those in the control group, and the difference was statistically significant （P〈0.05）. There was no significant difference in the incidence of gastrointestinal reactions, liver function im- pairment, fever, and leukopenia between the two groups （P〉0.05）. Conclusion The hepatic arterial chemoembolization combined with deep hyperthermia in patients with advanced primary liver cancer has more accurate clinical effect, which not only can reduce the tumor, but also can improve the quality of life. It is a treatment program worthy of clini- cal promotion and application.